WallStreetZenWallStreetZen

NYSE: NVS
Novartis Ag Stock

Overview
ForecastEarningsDividendOwnership
$97.90+0.89 (+0.92%)
Updated Nov 30, 2023
NVS Price
$97.90
Fair Value Price
N/A
Market Cap
$201.23B
52 Week Low
$79.98
52 Week High
$105.61
P/E
26.18x
P/B
5.27x
P/S
4.01x
PEG
1x
Dividend Yield
3.54%
Revenue
$52.32B
Earnings
$7.84B
Gross Margin
70.4%
Operating Margin
18.97%
Profit Margin
15%
Debt to Equity
1.95
Operating Cash Flow
$16B
Beta
0.53
Next Earnings
Jan 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A

NVS Overview

Novartis AG manufactures prescription medications related to oncology, ophthalmology, neuroscience, immunology, respiratory, and cardio-metabolic medicine. Novartis AG is collaborating with Alnylam Pharmaceuticals to commercialize inclisiran. The company is also collaborating with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Zen Score

–
Industry Average (42)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NVS ($97.90) is trading above its intrinsic value of $52.16, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVS is good value based on its earnings relative to its share price (26.18x), compared to the US market average (29.24x)
P/E vs Market Valuation
NVS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more NVS due diligence checks available for Premium users.

Be the first to know about important NVS news, forecast changes, insider trades & much more!

NVS News

Valuation

NVS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
26.18x
Industry
43.24x
Market
29.24x
NVS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NVS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

NVS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.27x
Industry
5.34x
NVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NVS price to earnings growth (PEG)

For valuing profitable companies with growth potential
NVS is good value based... subscribe to Premium to read more.
PEG Value Valuation

NVS's financial health

Profit margin

Revenue
$12.1B
Net Income
$1.8B
Profit Margin
14.6%
NVS's Earnings (EBIT) of $9.92B... subscribe to Premium to read more.
Interest Coverage Financials
NVS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$112.7B
Liabilities
$74.5B
Debt to equity
1.95
NVS's short-term liabilities ($48.39B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVS's short-term assets ($45.66B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$5.4B
Investing
-$2.2B
Financing
-$832.0M
NVS's operating cash flow ($16.02B)... subscribe to Premium to read more.
Debt Coverage Financials

NVS vs General Drug Manufacturer Stocks

TickerMarket Cap1d %P/EP/B
NVS$201.23B+0.92%26.18x5.27x
AZN$200.10B+0.73%33.91x5.38x
PFE$172.05B+1.30%16.47x1.77x
ABBV$251.39B+2.81%38.90x20.79x
AMGN$144.31B+1.14%19.06x18.85x
View Top General Drug Manufacturer Stocks

Novartis Ag Stock FAQ

What is Novartis Ag's quote symbol?

(NYSE: NVS) Novartis Ag trades on the NYSE under the ticker symbol NVS. Novartis Ag stock quotes can also be displayed as NYSE: NVS.

If you're new to stock investing, here's how to buy Novartis Ag stock.

What is the 52 week high and low for Novartis Ag (NYSE: NVS)?

(NYSE: NVS) Novartis Ag's 52-week high was $105.61, and its 52-week low was $79.98. It is currently -7.3% from its 52-week high and 22.41% from its 52-week low.

How much is Novartis Ag stock worth today?

(NYSE: NVS) Novartis Ag currently has 2,055,500,000 outstanding shares. With Novartis Ag stock trading at $97.90 per share, the total value of Novartis Ag stock (market capitalization) is $201.23B.

Novartis Ag stock was originally listed at a price of $40.69 in Dec 31, 1997. If you had invested in Novartis Ag stock at $40.69, your return over the last 25 years would have been 140.63%, for an annualized return of 3.57% (not including any dividends or dividend reinvestments).

How much is Novartis Ag's stock price per share?

(NYSE: NVS) Novartis Ag stock price per share is $97.90 today (as of Nov 30, 2023).

What is Novartis Ag's Market Cap?

(NYSE: NVS) Novartis Ag's market cap is $201.23B, as of Dec 2, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Novartis Ag's market cap is calculated by multiplying NVS's current stock price of $97.90 by NVS's total outstanding shares of 2,055,500,000.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.